Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ).
Jacobio Pharmaceuticals Group Co., Ltd. held its Annual General Meeting on June 10, 2025, where all proposed resolutions were passed by a poll vote. Key outcomes included the re-election of directors, reappointment of the auditor, and granting of mandates to issue and repurchase shares. These decisions are indicative of the company’s strategic direction and governance stability, potentially impacting its operational capabilities and shareholder value.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. The company focuses on developing innovative drugs and therapies, with a market presence in Hong Kong as indicated by its listing on the Hong Kong Stock Exchange.
Average Trading Volume: 8,138,282
Technical Sentiment Signal: Hold
Current Market Cap: HK$4.05B
Learn more about 1167 stock on TipRanks’ Stock Analysis page.